Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks. -- Barrons.com

Dow Jones02-04 01:04

By Mackenzie Tatananni

Novo Nordisk surprised investors Tuesday as the Ozempic maker posted its full-year earnings one day ahead of schedule, topping sales forecasts for 2025.

Novo reported 2025 sales of 309.1 billion Danish krone (DKK) for 2025, above the DKK 307.3 billion analysts had anticipated, according to FactSet. Operating profit fell 1% in local currency and increased 6% at constant exchange rates to DKK 127.7 billion.

Trading was halted ahead of the report. After resuming trading, Novo's U.S.-listed shares fell 11% to $52.66.

This is breaking news. Please check back for updates.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 03, 2026 12:04 ET (17:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608065278?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608065278","market":"fut","top_or_hot":-1,"title":"Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> surprised investors Tuesday as the Ozempic maker posted its full-year earnings one day ahead of schedule, topping sales forecasts for 2025. \n</p>\n<p>\n  Novo reported 2025 sales of 309.1 billion Danish krone (DKK) for 2025, above the DKK 307.3 billion analysts had anticipated, according to FactSet. Operating profit fell 1% in local currency and increased 6% at constant exchange rates to DKK 127.7 billion. \n</p>\n<p>\n  Trading was halted ahead of the report. After resuming trading, Novo's U.S.-listed shares fell 11% to $52.66. \n</p>\n<p>\n  This is breaking news. Please check back for updates. \n</p>\n<p>\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 12:04 ET (17:04 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-04 01:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> surprised investors Tuesday as the Ozempic maker posted its full-year earnings one day ahead of schedule, topping sales forecasts for 2025. \n</p>\n<p>\n  Novo reported 2025 sales of 309.1 billion Danish krone (DKK) for 2025, above the DKK 307.3 billion analysts had anticipated, according to FactSet. Operating profit fell 1% in local currency and increased 6% at constant exchange rates to DKK 127.7 billion. \n</p>\n<p>\n  Trading was halted ahead of the report. After resuming trading, Novo's U.S.-listed shares fell 11% to $52.66. \n</p>\n<p>\n  This is breaking news. Please check back for updates. \n</p>\n<p>\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 12:04 ET (17:04 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608065278","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608065278","pubTimestamp":1770138240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk surprised investors Tuesday as the Ozempic maker posted its full-year earnings one day ahead of schedule, topping sales forecasts for 2025.Novo reported 2025 sales of 309.1 billion Danish krone  for 2025, above the DKK 307.3 billion analysts had anticipated, according to FactSet. Operating profit fell 1% in local currency and increased 6% at constant exchange rates to DKK 127.7 billion.Trading was halted ahead of the report. After resuming trading, Novo's U.S.-listed shares fell 11% to $52.66.This is breaking news. Please check back for updates.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"诺和诺德公布2025年销售额好于预期。股票下跌。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"By Mackenzie Tatananni \n\n\nNovo Nordisk surprised investors Tuesday as the Ozempic maker posted its full-year earnings one day ahead of schedule, topping sales forecasts for 2025. \n\n\n  Novo reported 2025 sales of 309.1 billion Danish krone (DKK) for 2025, above the DKK 307.3 billion analysts had anticipated, according to FactSet. Operating profit fell 1% in local currency and increased 6% at constant exchange rates to DKK 127.7 billion. \n\n\n  Trading was halted ahead of the report. After resuming trading, Novo's U.S.-listed shares fell 11% to $52.66. \n\n\n  This is breaking news. Please check back for updates. \n\n\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 12:04 ET (17:04 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608065278","isCrawlerRequest":true}